The return of the FT Global Pharmaceutical and Biotechnology Conference
Posted: 28 July 2017 | Financial Times | No comments yet
The FT Global Pharmaceutical and Biotechnology Conference, now in its 35th successful year, will be returning to London this November…
With over 40 confirmed speakers so far, this year’s conference is set to be the most impactful to date. It brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in this new era of unprecedented disruption and uncertainty.
Confirmed speakers include:
> Bahija Jallal, Executive Vice President, AstraZeneca and Head, MedImmune
> Simon Stevens, Chief Executive Officer, NHS England
> Flemming Ornskov, Chief Executive Officer, Shire
> Andy Schmeltz, Senior Vice President, Patient and Health Impact, Pfizer
> Steven Moran, Chief Strategy Officer, Novartis
> Vivek Ramaswamy, Founder & CEO, Roivant Sciences
> Régis Senegou, Chief Executive Officer, Sivan Innovation
> Bélén Garijo, Member of the Board and CEO, Healthcare, Merck
> André Choulika, Chairman and Chief Executive Officer, Cellectis
> Richard Mason, Head of Johnson & Johnson Innovation EMEA
Speaking on last year’s conference, Stefan Oschmann, Vice Chairman of the Executive Board & Deputy CEO, Merck said:
“The FT conference is one of the most important conferences in Europe and it’s a no-brainer that people participate in this event.”
Last year’s attendees included: AbbVie; AstraZeneca; Bayer; Biogen; Capella Bioscience; EFPIA; European Medicines Agency; GlaxoSmithKline; Google; Johnson & Johnson Innovation; Novo Nordisk; Pfizer; Roche; and Sanofi and Shire.
This year’s conference will be taking place on 09-10 November 2017 in London.
For more information and how to book, visit live.ft.com/PharmaBio
